Related Experiment Videos

PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations

Ana Velasco1, Elena Bussaglia, Judit Pallares

  • 1Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, Lleida, Spain.

Human Pathology
|September 5, 2006
PubMed

Insights

Mutations in the PIK3CA gene are common in endometrial cancer and often occur alongside PTEN gene alterations. These PIK3CA mutations may contribute to tumor development, especially when PTEN is only partially inactivated.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Alterations in the phosphatidylinositol 3-kinase (PI3K)/AKT pathway are frequent in endometrial carcinoma.
  • PTEN tumor suppressor gene inactivation and PIK3CA gene mutations are key events in endometrial tumorigenesis.
  • The interplay between PIK3CA mutations and PTEN inactivation status (monoallelic vs. biallelic) in endometrial cancer requires further elucidation.

Purpose of the Study:

  • To investigate the frequency and spectrum of PIK3CA mutations in endometrial carcinomas.
  • To assess the relationship between PIK3CA mutational status and PTEN alterations (including monoallelic and biallelic inactivation).
  • To explore the correlation of PIK3CA mutations with microsatellite instability and mutations in other key genes like K-RAS and CTNNB-1.

Main Methods:

  • Analysis of PIK3CA mutational status in 33 endometrial carcinoma samples.
  • Assessment of PTEN alterations, including loss of heterozygosity and promoter hypermethylation, to determine inactivation status.
  • Screening for microsatellite instability and mutations in PTEN, K-RAS, and CTNNB-1.

Main Results:

  • PIK3CA mutations were detected in 24% of endometrial carcinomas, predominantly in exon 20.
  • PTEN alterations were found in 57% of cases, with 11 exhibiting biallelic inactivation and 8 showing monoallelic alteration.
  • PIK3CA mutations were observed in conjunction with both monoallelic and biallelic PTEN inactivation, as well as in tumors with wild-type PTEN. PIK3CA and K-RAS mutations were mutually exclusive.

Conclusions:

  • PIK3CA mutations are a frequent event in endometrial carcinoma.
  • PIK3CA mutations may exert an additive effect on tumorigenesis, particularly in the context of PTEN monoallelic inactivation.
  • These findings highlight the complex genetic landscape of endometrial cancer and the significance of the PI3K/AKT pathway.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...